Shortly after, in 2017, two other PARP inhibitors, Rucaparib and Niraparib, were FDA-approved for use in cancer patients with BRCA mutation as well as for non-carriers of BRCA mutations to treat primary peritoneal cancer, fallopian tube, or recurrent epithelial ovarian cancer resistant to cisplatin chemotherapy [91,92]. The gene discussed is PARP1; the disease is cancer.